DSM to further explore growth opportunities in China
(Thomson Reuters ONE) - Royal DSM N.V., the global Life Sciences and Materials Sciencescompany headquartered in the Netherlands, today announces that thecontracts to establish nutrition and anti-infectives joint venturesin China with North China Pharmaceutical Group Corporation Ltd.(NCPC) are suspended. DSM will continue its search for partners inChina as the company prepares for further growth in the country,which in 2008 represented 8% of DSM's net sales.Jan Zuidam, Deputy Chairman of the DSM Managing Board, comments:"China is transforming from the world's manufacturing base into oneof the world's leading economies with one of the highest growthrates. Economic prosperity and strong domestic demand, driven by afast-rising income level combined with an increased focus oninnovation, are expected to fuel economic growth in China for thecoming decades. DSM is very well positioned in China and iscontinuously seeking opportunities to further improve its position."In 2004 DSM announced its intention to form a strategic partnershipwith NCPC. Earlier this year the contracts for joint ventures in theareas of nutritional products (vitamins) and anti-infectives weresigned.DSM has been informed that, due to the recent change in the ownershipof NCPC, the implementation of these contracts has been delayed andpossibly cannot be effectuated within a reasonable timeframe.Although still interested in the cooperation, the contracts aresuspended, while both parties are maintaining their ongoing businessrelationships. At the same time, DSM will look for alternativesolutions for the prospective partnerships.DSM will continue to explore other opportunities for further growthin China through strategic cooperation, also in the areas ofnutritional products and anti-infectives.DSM in ChinaDSM began trading with China in 1963. Today, DSM has invested inChina for over a decade. DSM has its China regional headquarters andR&D center in Shanghai. The company currently has 14 manufacturingsites in China and employs nearly 4,000 people. DSM's business isgrowing healthily and steadily in China with revenue of above USD 1.1billion in 2008. In addition, DSM is committed to China's sustainabledevelopment. More information: www.dsm.com.cn.DSM - the Life Sciences and Materials Sciences CompanyRoyal DSM N.V. creates innovative products and services in LifeSciences and Materials Sciences that contribute to the quality oflife. DSM's products and services are used globally in a wide rangeof markets and applications, supporting a healthier, more sustainableand more enjoyable way of life. End markets include human and animalnutrition and health, personal care, pharmaceuticals, automotive,coatings and paint, electrical and electronics, life protection andhousing. DSM has annual net sales of EUR 9.3 billion and employs some23,500 people worldwide. The company is headquartered in theNetherlands, with locations on five continents. DSM is listed onEuronext Amsterdam. More information: www.dsm.com.For more information:DSM Corporate Communications DSM Investor RelationsHerman Betten Hans Vossentel. +31 (0) 45 tel. +31 (0) 45 57828645782017 fax +31 (0) 45 5782595fax +31 (0) 45 e-mail5740680 investor.relations(at)dsm.come-mail media.relations(at)dsm.comDSM China CommunicationsRobyn Wangtel. +86 21 6141 8003e-mail china.communications(at)dsm.comhttp://hugin.info/130663/R/1351412/326609.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 30.10.2009 - 08:15 Uhr
Sprache: Deutsch
News-ID 7666
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 322 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSM to further explore growth opportunities in China"
steht unter der journalistisch-redaktionellen Verantwortung von
DSM N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
